Ivax Says Paclitaxel Will Stay On Market Despite Appeals Court Ruling

FDA does not want to remove generic versions of Bristol-Myers Squibb's Taxol from the market, Ivax maintained following an appeals court ruling directing the agency to vacate the approval of Ivax' ANDA for paclitaxel